Full text
Earnings transcript
Read the complete earnings call transcript.
COO
The Cooper Companies, Inc.
$54.37
0.07
(0.13%)
| Exchange: | NASDAQ |
| Market Cap: | 10.604B |
| Shares Outstanding: | 13.968M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | Medical – Instruments & SuppliesView industry performance | |||||
| CEO: | Albert G. White | |||||
| Full Time Employees: | 15000 | |||||
| Address: |
| |||||
| Website: | https://www.coopercos.com |
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women’s and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment’s offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
Click to read more…
Revenue Segmentation
COO full analysis
Hey everyone, welcome back to MarketSnap. Cooper Companies just did something that landed it as the single worst performer in the entire S&P 500 for a day — and with the stock down more than twenty percent over the past month, investors are asking a very simple question: is this a broken story, or is the market throwing out a fifty-year-old contact lens and surgical device business with the bathwater? Today we're walking through the full picture — the business,…
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 3,593,200 | 3,895,400 | 4,092,400 |
| Gross Profit | 2,357,900 | 2,595,700 | 2,482,900 |
| EBITDA | 885,900 | 1,071,700 | 1,053,400 |
| Operating Income | 533,100 | 705,700 | 682,900 |
| Net Income | 294,200 | 392,300 | 374,900 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 11,658,900 | 12,315,200 | 12,394,800 |
| Total Liabilities | 4,107,900 | 4,231,600 | 4,155,700 |
| Total Stockholders Equity | 7,550,800 | 8,083,400 | 8,238,900 |
| Total Debt | 2,569,200 | 2,583,700 | 47,800 |
| Cash and Cash Equivalents | 120,800 | 107,600 | 110,600 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 607,500 | 709,300 | 796,100 |
| Capital Expenditure | -392,500 | -421,200 | -362,400 |
| Free Cash Flow | 215,000 | 288,100 | 433,700 |
| Net Income | 294,200 | 392,300 | 374,900 |
| Net Change in Cash | -17,700 | -13,200 | 2,900 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 5,290,557.614 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 5,388,602.601 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 5,348,000 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 2,202,182.032 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 2,242,379.356 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 2,225,733.027 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 1,283,820.006 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 1,314,850.006 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 1,302,000.006 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 2,147,337.818 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 2,187,132.434 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 2,170,652.602 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 6.510 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 6.570 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 6.420 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 9 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 3 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Record Q1 2025 revenues of $965 million signal sustained top-line momentum, supported by product innovation and market expansion as highlighted in the earnings call summary. This reflects effective operational execution and a positive growth trajectory.
- Strong profitability metrics, including positive ROE and ROIC (TTM), indicate efficient capital deployment and shareholder value creation. Gross and net profit margins (TTM) suggest pricing power and cost discipline within the medical device sector.
- Healthy free cash flow yield (TTM) and operating cash flow provide internal funding capacity for R&D, capex, and potential dividend payments, reducing reliance on external financing.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates COO intrinsic value between $82.85 – $94.65 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about COO valuation
Is The Cooper Companies, Inc. (COO) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for The Cooper Companies, Inc. (COO) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is COO a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether COO trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is COO’s P/E ratio?
You can see COO’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for COO?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is COO a good long-term investment?
Whether COO fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
COO
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.13
Trading Metrics:
| Open: | 54.32 | Previous Close: | 54.3 | |
| Day Low: | 53.85 | Day High: | 54.75 | |
| Year Low: | 51.01 | Year High: | 89.83 | |
| Price Avg 50: | 65.7 | Price Avg 200: | 70.85 | |
| Volume: | 3.183M | Average Volume: | 3.327M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
